http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2564018-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02 |
| filingDate | 2011-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7e1e7438a87e3a0b79f516a2c4244d5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb62b9b5e13abdcfc96d5ae7c64c1046 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c1b04758b8ce0dc185902b554a2d414 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3441e05c8099deac0ba44a4e9646f1b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4669f2f17037a017203d0fec0b9efae1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e58fb34db5077828b5c005efa741afaa |
| publicationDate | 2015-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2564018-C2 |
| titleOfInvention | Carboxylic acid derivatives containing 2,5-substituted oxazolopyrimidine ring |
| abstract | FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to oxazolopyrimidine compounds of formula I in any of its stereoisomer forms or its physiologically acceptable salt, wherein A is specified in NH, O and S; X is specified in (C 1 -C 6 )-alkanediyl, (C 2 -C 6 )-alkenediyl, and (C 1 -C 6 )-alkanediyloxy, wherein oxygen atom of (C 1 -C 6 )-alkanediyloxy group is related to the group R 2 ; R 1 is specified in hydrogen and (C 1 -C 4 )-alkyl; R 2 is specified in phenylene, which is optionally substituted in one or more carbon atoms in the ring by identical or different substitutes R 22 ; R 3 is specified in (C 1 -C 6 )-alkyl optionally substituted by 1-3 fluorine atoms, or R 3 is a residue of a saturated or unsaturated 5-merous - 10-merous monocyclic or bicyclic ring, which contains 0, 1 or 2 heteroatoms in the ring specified in N, O and S, and represents cyclopentyl, indanyl, phenyl, naphthyl, thiazole, isothiazole, pyridyl, benzothiazole or quinoline, and wherein a residue of the ring is optionally substituted in one or two carbon atoms in the ring by identical or different substitutes R 31 ; R 22 is specified in (C 1 -C 4 )-alkyl optionally substituted by 1-3 fluorine atoms; R 31 is specified in halogen, (C 1 -C 4 )-alkyl optionally substituted by 1-3 fluorine atoms, (C 1 -C 4 )-alkyloxy optionally substituted by 1-3 fluorine atoms, and (C 1 -C 4 )-alkyl-S(O) m - optionally substituted by 1-3 fluorine atoms; m is equal to 0. The invention also refers to a pharmaceutical composition containing the compounds of formula I, and to a method for producing the compounds of formula I. n EFFECT: producing the compounds of formula I applicable for EDG-1 receptor activation. n 14 cl, 2 tbl, 2 ex |
| priorityDate | 2010-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 642.